BLUE - Is bluebird bio a Buy for Summer 2021?
bluebird bio (NASDAQ: BLUE) stock has fallen on hard times due to seemingly never-ending issues with its gene therapy, LentiGlobin. The stem-cell-derived transfusion is in phase 1/2 clinical trials for treating sickle cell disease (SCD) and received conditional marketing approval from the European Medical Agency (EMA) for targeting beta thalassemia. Both diseases are rare blood disorders causing hemoglobin anomalies.
Despite a heavy and consistent sell-off, I think Bluebird stock might be severely undervalued . Let's look at what investors are missing out on.
Image source: Getty Images.
For further details see:
Is bluebird bio a Buy for Summer 2021?